Drug-eluting stents are widely used for the treatment of coronary artery disease to reduce the risk of restenosis found with bare-metal stents. Nevertheless, there are concerns about device deliverability and safety with the initial generation of drug-eluting stents. The second-generation Xience V everolimus-eluting stent incorporates advanced design features such as a cobalt-chromium stent platform coated with an antirestenotic drug, everolimus, incorporated into a biocompatible polymer with a long history of medical use. The efficacy of the stent has been demonstrated with low rates of angiographic restenosis, whilst randomized trials comparing the Xience V everolimus-eluting stent to the first-generation Taxus paclitaxel-eluting stent have found a reduction in repeat revascularization rates. Further randomized trials, including 'all-comer' patients and registries of unselected patients are currently further evaluating the efficacy and safety of the Xience V stent in high-risk, complex cases.
Kuniaki Takahashi, Patrick W. Serruys, Norihiro Kogame, Paweł Buszman, Philipp Lurz, Gillian A.J. Jessurun, Karel T. Koch, Roland P.T. Troquay, Bas Hamer, Ton Oude Ophuis, Krzysztof Milewski, Sjoerd H. Hofma, Joanna J. Wykrzykowska, Yoshinobu Onuma, Robbert J. de Winter, William Wijns
Bimmer E. Claessen, Pieter C. Smits, Dean J. Kereiakes, Helen Parise, Martin Fahy, Elvin Kedhi, Patrick W. Serruys, Alexandra J. Lansky, Ecaterina Cristea, Krishnankutty Sudhir, Poornima Sood, Charles A. Simonton, Gregg W. Stone
Scot Garg, Patrick W. Serruys, Yoshinobu Onuma, Cécile Dorange, Susan Veldhof, Karine Miquel‐Hébert, Krishnankutty Sudhir, Jean Boland, Kurt Huber, Eulogio Garcı́a, Jan A.M. te Riele
Discussion(0)
No comments yet. Be the first to comment.